Dogwood Therapeutics Reports Positive Interim Phase 2b Results for Halneuron in Chemotherapy-Induced Neuropathic Pain
Reuters
Dec 22, 2025
<a href="https://laohu8.com/S/DWTX">Dogwood Therapeutics</a> Reports Positive Interim Phase 2b Results for Halneuron in Chemotherapy-Induced Neuropathic Pain
Dogwood Therapeutics Inc. announced positive interim results from its ongoing Phase 2b clinical trial evaluating Halneuron® in patients with chemotherapy-induced neuropathic pain (CINP). According to the company, an independent statistical review committee found that patients treated with Halneuron® showed separation from placebo in pain improvement assessments over the four-week study period. The interim analysis was based on data from 97 patients who had completed treatment. The company reported a study dropout rate of approximately 4.4%, which it noted is lower than rates typically observed with other FDA-approved chronic pain medications. Dogwood Therapeutics expects to present top-line results from the trial in the third quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9616014-en) on December 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.